ACCESS Newswire (Fri, 24-Oct 7:30 AM ET)
Market Chameleon (Thu, 16-Oct 5:54 AM ET)
ACCESS Newswire (Thu, 16-Oct 7:30 AM ET)
ACCESS Newswire (Tue, 30-Sep 7:30 AM ET)
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Mira Pharmaceuticals trades on the NASDAQ stock market under the symbol MIRA.
As of December 24, 2025, MIRA stock price declined to $1.57 with 22,597 million shares trading.
MIRA has a beta of 1.90, meaning it tends to be more sensitive to market movements. MIRA has a correlation of 0.18 to the broad based SPY ETF.
MIRA has a market cap of $65.75 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that MIRA belongs to (by Net Assets): VXF, VTI.
MIRA has outperformed the market in the last year with a price return of +49.5% while the SPY ETF gained +17.2%. MIRA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.8% and +7.5%, respectively, while the SPY returned +4.3% and +1.3%, respectively.
MIRA support price is $1.53 and resistance is $1.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIRA shares will trade within this expected range on the day.